Lancet Respiratory Medicine September 01, 2021

Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial

Vincent C Marconi, Athimalaipet V Ramanan, Stephanie de Bono, Cynthia E Kartman, Venkatesh Krishnan, et al.

Bottom Line

In hospitalised adults with COVID-19, baricitinib did not significantly reduce the primary composite endpoint of disease progression compared to placebo, but it demonstrated a robust and clinically significant 38% relative reduction in 28-day all-cause mortality.

Key Findings

1. Overall, 27.8% of participants receiving baricitinib and 30.5% receiving placebo progressed to the primary composite endpoint of high-flow oxygen, non-invasive ventilation, invasive mechanical ventilation, or death by day 28 (OR 0.85; 95% CI 0.67-1.08; p=0.18) [2.1.1].

2. 28-day all-cause mortality was significantly lower in the baricitinib group (8.1%, n=62) compared to the placebo group (13.1%, n=100), yielding a hazard ratio of 0.57 (95% CI 0.41-0.78; nominal p=0.0018) and a 38.2% relative reduction in mortality.

3. The 60-day all-cause mortality remained significantly lower for patients treated with baricitinib (10%, n=79) versus placebo (15%, n=116) (HR 0.62; 95% CI 0.47-0.83; p=0.0050).

4. Safety profiles were comparable; frequencies of serious adverse events (15% vs 18%), serious infections (9% vs 10%), and venous thromboembolic events (3% vs 3%) were similar between the baricitinib and placebo groups, respectively.

Study Design

Design

RCT

Double-Blind

Sample

1,525

Patients

Duration

28 days

Median

Setting

12 countries

Population Hospitalised adults with COVID-19 receiving standard of care (baseline ordinal scale 4, 5, or 6; not requiring invasive mechanical ventilation at baseline)

Intervention Baricitinib (4 mg) once daily for up to 14 days + standard of care

Comparator Matched placebo once daily for up to 14 days + standard of care

Outcome Composite of progression to high-flow oxygen, non-invasive ventilation, invasive mechanical ventilation, or death by day 28

Study Limitations

• The trial did not meet statistical significance for its primary composite endpoint, meaning the mortality reduction, though large and highly significant, was technically a secondary outcome finding subject to hierarchical testing limitations.

• The standard of care evolved significantly during the enrollment period (e.g., increasing routine use of dexamethasone), which may have shifted baseline risks and event rates.

• The overall event rate for progression was lower than originally anticipated in the sample size calculations, potentially leaving the primary endpoint underpowered.

• The primary study population excluded patients who already required invasive mechanical ventilation or ECMO at baseline (though they were investigated in a subsequent exploratory sub-study).

Clinical Significance

Despite missing the primary endpoint for disease progression, COV-BARRIER established baricitinib as a highly effective, life-saving therapy for hospitalised patients with COVID-19. Its robust 38% reduction in mortality—one of the largest relative mortality benefits observed in COVID-19 trials—provided a crucial oral anti-inflammatory alternative to IL-6 inhibitors, leading to standard-of-care status and major updates in international treatment guidelines.

Historical Context

Early in the pandemic, artificial intelligence-assisted drug screening identified baricitinib, an oral JAK1/JAK2 inhibitor used for rheumatoid arthritis, as a promising COVID-19 candidate due to its potential to halt cytokine storms and inhibit viral entry. The prior ACTT-2 trial demonstrated that baricitinib plus remdesivir hastened clinical recovery compared to remdesivir alone, but it was not powered to assess mortality. COV-BARRIER was designed to test baricitinib against placebo on top of the newly established standard of care (which predominantly included dexamethasone). Its striking mortality benefit validated the role of targeted immunomodulation in severe COVID-19 and secured global regulatory authorizations.

Guided Discussion

High-yield insights from every perspective

Med Student

Medical Student

Baricitinib is a Janus kinase (JAK) inhibitor. What is the proposed dual mechanism of action of baricitinib in the context of COVID-19 that made it a compelling therapeutic candidate for the COV-BARRIER trial?

Key Response

Baricitinib inhibits JAK1 and JAK2, blocking downstream STAT pathways to reduce the cytokine storm and hyperinflammation. Additionally, it has antiviral properties by inhibiting AAK1 and GAK, which are regulators of endocytosis, thereby potentially reducing SARS-CoV-2 viral entry into host cells.

Resident

The COV-BARRIER trial evaluated baricitinib in addition to standard of care. In a hospitalized COVID-19 patient requiring supplemental oxygen, how does this finding influence your choice between baricitinib and dexamethasone, and how should they be used together?

Key Response

Most patients in the COV-BARRIER trial were already receiving background corticosteroids like dexamethasone. Baricitinib is not a replacement for dexamethasone but an adjunctive immunomodulator. Residents should recognize that adding baricitinib to dexamethasone provides an additive mortality benefit for hospitalized patients with systemic inflammation and escalating oxygen requirements.

Fellow

A notable finding in the COV-BARRIER trial is the dissociation between the primary endpoint (no significant reduction in progression to NIV/IMV/death) and the secondary endpoint (significant 38 percent reduction in 28-day mortality). What pathophysiological dynamics might explain why a drug fails to prevent progression to mechanical ventilation but significantly improves overall survival?

Key Response

This paradox suggests that while baricitinib may not rapidly halt the initial localized trajectory of acute lung injury necessitating ventilatory support, its potent systemic anti-inflammatory effects prevent the irreversible multi-organ failure, severe thrombosis, and hyperinflammatory shock that ultimately drive late mortality.

Attending

Given that the trial missed its primary composite endpoint but demonstrated a profound reduction in mortality, how do you navigate the evidence-based medicine dilemma of adopting a practice-changing therapy based primarily on a nominally positive secondary endpoint?

Key Response

In strict frequentist frameworks, missing a primary endpoint renders secondary analyses hypothesis-generating due to alpha spending. However, in clinical practice with a definitive, highly patient-important outcome like all-cause mortality showing robust statistical significance and clinical magnitude, attendings must weigh the real-world risk of withholding a life-saving therapy against standard statistical rigidity.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD

The trial utilized a composite primary endpoint including disease progression (high-flow oxygen, NIV, IMV) and death. From a statistical and design perspective, what are the pitfalls of combining morbidity and mortality endpoints in a viral ARDS trial, and how did it impact this trial's power?

Key Response

Composite endpoints can severely dilute the treatment effect if the intervention affects components divergently or if the most frequent but least severe component (e.g., oxygen escalation) dominates the event rate but is unaffected by the drug. In COV-BARRIER, the high noise of respiratory progression likely masked the true signal in mortality, leading to an underpowered primary analysis.

Journal Editor

As an editor, how do you critically evaluate the claim of a 38 percent relative reduction in mortality when the primary endpoint failed, considering the risks of multiplicity and Type I error inflation?

Key Response

A rigorous editor would flag that once the primary endpoint fails, subsequent p-values in hierarchical testing are technically nominal. The editor must demand transparency, ensuring the mortality benefit is biologically plausible, consistent across subgroups, and that the authors adequately caveat the hierarchical testing failure while contextualizing the clinical importance of the survival benefit.

Guideline Committee

Based on the mortality benefit seen in COV-BARRIER, how should clinical guidelines (e.g., NIH or WHO) position baricitinib relative to IL-6 inhibitors like tocilizumab in the treatment algorithm for hospitalized COVID-19 patients?

Key Response

The committee must evaluate whether JAK and IL-6 inhibitors are interchangeable. Current NIH guidelines give a strong recommendation for adding either baricitinib or tocilizumab to dexamethasone in patients with rapidly increasing oxygen needs. The robust mortality data from COV-BARRIER elevated baricitinib to an equivalent recommendation level as tocilizumab, offering a highly effective oral alternative to intravenous biologics.

Clinical Landscape

Noteworthy Related Trials

2020

ACTT-2 Trial

n = 1,033 · NEJM

Tested

Baricitinib plus Remdesivir

Population

Hospitalised adults with COVID-19

Comparator

Remdesivir plus Placebo

Endpoint

Time to recovery

Key result: Baricitinib plus remdesivir was superior to remdesivir alone in reducing recovery time and accelerating improvement in clinical status.

2020

RECOVERY Trial (Dexamethasone)

n = 6,425 · NEJM

Tested

Dexamethasone 6mg daily

Population

Hospitalised patients with COVID-19

Comparator

Usual care

Endpoint

28-day mortality

Key result: Dexamethasone reduced 28-day mortality among patients receiving invasive mechanical ventilation or oxygen alone, but not among those receiving no respiratory support.

2021

REMAP-CAP Trial

n = 895 · NEJM

Tested

Tocilizumab or Sarilumab (IL-6 receptor antagonists)

Population

Critically ill adults with COVID-19 receiving organ support

Comparator

Standard care

Endpoint

Organ support-free days up to day 21

Key result: Treatment with IL-6 receptor antagonists improved clinical outcomes, including survival and time to hospital discharge, compared to standard care.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis